Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial.

Akira SezaiAtsushi TanakaTakumi ImaiKeisuke KidaHisakuni SekinoToyoaki MuroharaMasataka SataNorio SuzukiKoichi Nodenull null

Published in: Biomedicines (2022)

There was no significant difference in the effects of canagliflozin, relative to glimepiride, on NT-proBNP concentrations irrespective of baseline obesity. UMIN clinical trial registration number: UMIN000017669.

Keyphrases

clinical trial
body mass index
weight gain
phase ii
phase iii
study protocol
insulin resistance
metabolic syndrome
open label
weight loss
type diabetes
double blind
high fat diet induced
ejection fraction
physical activity
randomized controlled trial
skeletal muscle
placebo controlled